Rocket Lab's Revenue Is Soaring. So Why Is the Stock Sinking?

Rocket Lab’s Neutron rocket launch timing has reportedly slipped to early 2027, contributing to shares trading down ~58% from earlier-year highs despite 62% YoY revenue growth in the latest quarter. The company’s space systems segment led with $189.5M revenue vs $44.6M for launch, while its acquisition of Iridium Communications is framed as accelerating competition with Starlink. However, low gross margins, no history of profitability, and a still-rich valuation (P/S of 48) are cited as reasons not to “buy the dip” yet.

Analysis

The market is treating the delayed heavy-lift program as a credibility problem, not just a timing issue. That matters because the bull case depends on moving the company from niche launch economics toward a higher-throughput platform model; every quarter of slip extends the period where fixed launch infrastructure and pre-revenue capex dilute returns, which keeps the equity in a “story stock” bucket rather than a cash-flow compounder. In the near term, the stock will likely trade on schedule confidence more than on reported sales growth.

Second-order, the delay cedes mission share to better-capitalized incumbents and weakens the company’s ability to bundle launch with upstream hardware and subsystems. That shifts bargaining power back to customers and compresses pricing leverage across the broader space-services stack. If management leans harder on satellite services and adjacent manufacturing to fill the gap, investors may eventually revalue the business less like a launch disruptor and more like a lower-multiple aerospace integrator.

The contrarian point is that the selloff may still not fully reflect execution risk because the valuation is anchored to a rapid transition that now looks farther away. The key missing variable is not revenue growth, but margin trajectory and dilution: if the company must finance another two years of development without a visible step-up in launch cadence, the equity can stay structurally expensive even after further de-rating. A clean test campaign would be the only credible catalyst to reverse the tape; otherwise, any bounce is likely tactical rather than durable.

Key Decisions for Investors

• Short RKLB on strength over the next 1-3 months; use any relief rally into schedule-credibility headlines to initiate. Thesis breaks if the company demonstrably accelerates test cadence and stops slipping milestones.
• Prefer RKLB put spreads rather than outright short stock if you need defined risk; the setup is a time-decay trade against delayed commercialization, with the catalyst window concentrated over the next 2-4 quarters.
• Pair trade: short RKLB / long SPCX to isolate execution risk from sector beta. This works best if space-equity sentiment rebounds broadly while RKLB remains the laggard on milestone credibility.
• Watch IRDM as an event-driven special situation rather than a stand-alone long: any financing or structure that brings partner value to the surface could create a premium, but only if deal terms do not over-lever the combined story.
• Falsifier to the bearish view: a verified shift to on-time testing plus evidence of gross-margin expansion from the non-launch business in the next 1-2 earnings prints. Without that, the multiple likely remains vulnerable.